5 results
Primary: long-term safety and efficacy of SAR236553 in high risk patients with an insufficiently controlled hypercholestolemia despite treatment with existing lipid modifying drugs.Secondary objectives: effect on individual lipids, development of…
Primary Objectives:- To evaluate and compare the overall survival (OS) of subjects with advanced or metastatic adenocarcinoma of the pancreas when treated with JAK 1/2 Inhibitor in combination with capecitabine versus capecitabine alone.Secondary…
The purpose of the study is to confirm the skin test results in patients based on results of the control population of healthy volunteers never exposed to taspoglutide or any product with a similar mechanism of action.
Primary:to assess the reduction of initial study drug Cmax after administration of 20 mg study drug 10% SRF using three modified formulations as compared to the current Phase 3 formulation in healthy volunteers.Secondary:to assess the safety and…
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by SAR236553 in comparison withezetimibe after 24 weeks of treatment in patients with hypercholesterolemia